Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ocular Therapeutix (OCUL) Net Income towards Common Stockholders: 2013-2025

Historic Net Income towards Common Stockholders for Ocular Therapeutix (OCUL) over the last 13 years, with Sep 2025 value amounting to -$68.0 million.

  • Ocular Therapeutix's Net Income towards Common Stockholders fell 56.01% to -$68.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$247.3 million, marking a year-over-year decrease of 78.13%. This contributed to the annual value of -$165.1 million for FY2024, which is 83.96% down from last year.
  • According to the latest figures from Q3 2025, Ocular Therapeutix's Net Income towards Common Stockholders is -$68.0 million, which was down 1.14% from -$67.2 million recorded in Q2 2025.
  • In the past 5 years, Ocular Therapeutix's Net Income towards Common Stockholders ranged from a high of -$19.5 million in Q1 2022 and a low of -$68.0 million during Q3 2025.
  • Its 3-year average for Net Income towards Common Stockholders is -$41.2 million, with a median of -$40.8 million in 2024.
  • Per our database at Business Quant, Ocular Therapeutix's Net Income towards Common Stockholders climbed by 10.95% in 2022 and then plummeted by 115.51% in 2024.
  • Ocular Therapeutix's Net Income towards Common Stockholders (Quarterly) stood at -$19.7 million in 2021, then declined by 5.38% to -$20.8 million in 2022, then decreased by 9.42% to -$22.7 million in 2023, then slumped by 115.51% to -$49.0 million in 2024, then slumped by 56.01% to -$68.0 million in 2025.
  • Its Net Income towards Common Stockholders was -$68.0 million in Q3 2025, compared to -$67.2 million in Q2 2025 and -$63.1 million in Q1 2025.